Canaccord analyst Richard Close raised the firm’s price target on Quipt Home Medical (QIPT) to $3.65 from $2.30 and keeps a Hold rating on the shares. The firm updated its model after they reported 4QFY’25 results that beat expectations, in addition to a takeprivate transaction at $3.65 US per share with Kingswood Capital Management and Forager Capital Management.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QIPT:
- Quipt Home Medical: Hold Rating Highlights Fair Valuation Amid Take-Private Transaction and Market Conditions
- Buy Rating for Quipt Home Medical Amid Strategic Acquisition and Strong Financial Performance
- Midday Fly By: Intel eyes SambaNova, Cencora to acquire OneOncology
- Quipt Home Medical downgraded to Sell from Buy at Stifel
- Quipt Home Medical Agrees to Acquisition by Kingswood